1. Scientific Update

3. This program will include a discussion of off-label treatments not approved by the FDA for use in the US.

4. Introduction and Recap

5. Nonpharmacologic Interventions

6. Treatment of Bipolar Depression

7. FDA-Approved Agents for Bipolar Disorder in Children and Adolescents

8. Impact of Age on Antidepressant-Related Adverse Effects in Youth at Risk for Bipolar Disorder

9. Antidepressants for Depression Associated With Bipolar Disorder in Youth

10. Negative Reactions to Antidepressants Among Youth With Bipolar Disorder

11. Children's Depression Rating Scale

12. Lithium for Youth With Depression Associated With Bipolar I Disorder: An Open-Label Study

13. Lamotrigine for Youth With Bipolar Spectrum Disorders: An Open-Label Study

14. Quetiapine in Youth With Depressive Episodes Associated With Bipolar I Disorder

15. Quetiapine XR in Youth With Acute Bipolar Depression

16. OFC for Youth Aged 10 to 17 Years With Bipolar Depression

17. A Double-Blind, Placebo-Controlled Trial of Lurasidone for Youth With Bipolar Depression

18. Study Demographics and Primary Outcome Measure: CDRS-R Total Score

19. Most Common AEs* and Trial Safety Summary

20. Results of 2-Year Open-Label Study: Efficacy and Safety

21. Roles of Clinicians and the Community When Managing Pediatric Bipolar Depression

22. Concluding Remarks

23. Abbreviations

24. Abbreviations (cont)